Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?
Open Access
- 16 November 2024
- journal article
- review article
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 35 (3) , 103792
Abstract
No abstract availableKeywords
This publication has 116 references indexed in Scilit:
- Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without GoutJAMA Cardiology, 2023
- 2020 American College of Rheumatology Guideline for the Management of GoutArthritis Care & Research, 2020
- Population Impact Attributable to Modifiable Risk Factors for HyperuricemiaArthritis & Rheumatology, 2019
- U‐Shaped Association Between Serum Uric Acid Level and Risk of MortalityArthritis & Rheumatology, 2018
- Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional TreatmentJAMA, 2011
- Hyperuricemia and incident hypertension: A systematic review and meta‐analysisArthritis Care & Research, 2010
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trialArthritis Care & Research, 2008
- Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged MenArchives of internal medicine (1960), 2004
- The effect of mini-dose aspirin on renal function and uric acid handling in elderly patientsArthritis & Rheumatism, 2000
- Trends in serum uric acid levelsArthritis & Rheumatism, 1983